Clinical Trial Detail

NCT ID NCT02309892
Title A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Helix BioPharma Corporation
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + L-DOS47 + Pemetrexed Disodium

Age Groups: senior adult

No variant requirements are available.